07 November 2019
Visiongain has launched a new pharma report Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029: Mammalian Cell Cultures, Microbial Fermentations, and Other Expression Systems; Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines, and Others Therapeutic Areas.
The growth of the biosimilars market in the EU and the rise of generics will have a big effect on the biotech manufacturing services market. Consolidation as a strategy gives not only manufacturing capabilities, but access to cutting-edge technology and helps foster and establish relationships that can be used to enter new markets. Outsourcing as a strategy to reduce costs and increase efficiency can be a strength for biopharmaceutical companies. This trend in outsourcing will shift from the traditional model of using EU and US CMOs to outsourcing from lower emerging market CMOs, especially in Asia.
The lead analyst of the report commented "Strengths in the biotech contract manufacturing market, from the perspective of the CMOs, stem from the demand for lower cost manufacturing from companies of all sizes. This demand will continue to rise in the coming 10 years, Visiongain believes. CMOs can offer significant advantages in terms of cost and manufacturing flexibility for companies. Additionally, with many CMOs in the market, the range of services available to pharma companies is broad - CMOs have many opportunities to appeal to these pharma clients. CMOs can choose to specialise, providing a niche service or expertise in a particular formulation."
Leading companies featured in the report include Boehringer Ingelheim Abbvie, Boehringer Ingelheim BioXcellence, Catalent, Celltrion, Cytovance Biologics and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.